Skip to main content
Tvardi Therapeutics, Inc. logo

Tvardi Therapeutics, Inc. — Investor Relations & Filings

Ticker · TVRD ISIN · US1407553072 LEI · 549300COVOY41P0GZ881 IL Manufacturing
Open in API
Filings indexed 781 across all filing types
Latest filing 2025-04-18 Director's Dealing
Country US United States of America
Listing IL TVRD

About Tvardi Therapeutics, Inc.

https://tvarditherapeutics.com

Tvardi Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the development of novel, orally administered, small molecule therapies. The company's core approach is targeting STAT3 (Signal Transducer and Activator of Transcription 3), a key regulatory protein implicated in the progression of various diseases. Tvardi's therapeutic pipeline is designed to address conditions with significant unmet medical needs, including various forms of cancer and fibrosis-driven diseases. Its clinical trials are evaluating potential treatments for indications such as liver cancer and idiopathic pulmonary fibrosis (IPF).

Recent filings

Filing Released Lang Actions
Director's Dealing 2025
Director's Dealing
2025-04-18 English
Major Shareholding Notification 2025
Major Shareholding Notification
2025-04-16 English
FORM 8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated April 15, 2025, reporting the completion of a merger between Cara Therapeutics, Inc. and Tvardi Therapeutics, Inc. It includes detailed descriptions of material definitive agreements entered into in connection with the merger, such as indemnification agreements, registration rights agreements, and license agreements with Baylor College of Medicine. The content focuses on corporate events and agreements related to the merger rather than financial results or earnings. Form 8-K filings are current reports used to announce major events that shareholders should know about. This document is not an annual or quarterly report, earnings release, or management discussion. It is a regulatory filing reporting a material corporate event and related agreements. Therefore, the appropriate classification is Regulatory Filings (RNS). The document length and detail support a high confidence in this classification.
2025-04-15 English
FORM 8-K
M&A Activity Classification · 95% confidence The document is a Form 8-K current report filed with the SEC by Cara Therapeutics, Inc. dated April 11, 2025. It discloses a merger agreement with Tvardi Therapeutics, Inc. and includes an investor presentation as an exhibit. The content focuses on the merger announcement and related investor information, not on full financial statements or detailed financial performance. The document is a regulatory filing to announce a significant corporate event (merger) and furnish related materials, but it is not a full merger proxy statement or tender offer filing (which would be classified under MA or TAR). The presence of an investor presentation related to the merger supports classification as a Capital/Financing Update or M&A Activity. However, since the document is a Form 8-K primarily disclosing the merger agreement and furnishing an investor presentation, the best fit is M&A Activity (TAR) which covers announcements and documents related to merger proposals or takeover bids. Confidence is high given the clear merger context and Form 8-K nature.
2025-04-11 English
FORM 8-K
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is a Form 8-K Current Report filed with the SEC by Cara Therapeutics, Inc. It reports the results of a Special Meeting of Stockholders held on April 1, 2025, including detailed voting results on multiple proposals related to a merger and equity plans. The document also includes references to attached exhibits containing audited financial statements, management's discussion and analysis, and unaudited pro forma financial information related to the merger. The primary content is the official announcement of voting results from the stockholders' meeting, which aligns with the category of Declaration of Voting Results & Voting Rights Announcements (DVA). The presence of detailed vote counts and the nature of the proposals confirm this classification. Although financial statements and MD&A are referenced as exhibits, the main document itself is not the full financial report but a current report announcing voting outcomes and related merger information.
2025-04-01 English
FORM 8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K current report filed with the SEC by Cara Therapeutics, Inc. It discusses updates related to a merger agreement with Tvardi Therapeutics, including supplemental disclosures to a proxy statement/prospectus filed on Form S-4. The document includes detailed information about the merger, board composition post-merger, legal proceedings related to the merger, and shareholder litigation. The content is focused on merger-related disclosures and legal updates rather than the merger proxy statement itself or the full merger agreement. The document is not a full annual or quarterly report, nor is it a simple announcement or certification. It is a regulatory filing providing material updates and supplemental disclosures related to a merger transaction. Given the nature of the content and the form type (8-K), the most appropriate classification is Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements and filings that do not fit other specific categories such as M&A filings or proxy statements themselves.
2025-03-24 English

Browse filings by year

18 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.